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Non Standard Abbreviations 
 
Non-standard Abbreviations and Acronyms 
AA  Arachidonic acid 
ADMA Asymmetric dimethylarginine 
COX  Cyclooxygenase 
DHA  Docosahexaenoic acid  
DP1  D-type prostanoid receptor 1 
EP  Prostaglandin E2 receptor 
EPA  Eicosapentaenoic acid  
HETE  Hydroxyeicosatraenoic acid 
IPA  Ingenuity Pathway Analysis 
LA  Linoleic acid 
LOX  Lipoxygenase 
LTB4   Leukotriene B4 
NO  Nitric oxide 
PCA  Principal Component Analysis 
PG  Prostaglandin 
PTGS Prostaglandin G/H synthase 
TP  Thromboxane receptor 
TX  Thromboxane  
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Abstract 
 
Aspirin prevents thrombosis by inhibiting platelet cyclooxygenase (COX)-1 activity and the production of 
thromboxane (Tx)A2, a pro-thrombotic eicosanoid. However, the non-platelet actions of aspirin limit its anti-
thrombotic effects. Here we used platelet-COX-1-ko mice to define the platelet and non-platelet eicosanoids 
affected by aspirin. Mass-spectrometry analysis demonstrated blood from platelet-COX-1-ko and global-COX-
1-ko mice produced similar eicosanoid profiles in vitro: e.g. formation of TxA2, prostaglandin (PG) F2, 11-
HETE and 15-HETE was absent in both platelet- and global-COX-1-ko mice. Conversely, in vivo, platelet-
COX-1-ko mice had a distinctly different profile from global-COX-1-ko or aspirin-treated control mice, notably 
significantly higher levels of PGI2 metabolite. Ingenuity Pathway Analysis predicted that platelet-COX-1-ko 
mice would be protected from thrombosis, forming less prothrombotic TxA2 and PGE2. Conversely, aspirin or 
lack of systemic COX-1 activity decreased the synthesis of anti-aggregatory PGI2 and PGD2 at non-platelet sites 
leading to predicted thrombosis increase. In vitro and in vivo thrombosis studies proved these predictions. 
Overall, we have established the eicosanoid profiles linked to inhibition of COX-1 in platelets and in the 
remainder of the cardiovascular system and linked them to anti- and pro-thrombotic effects of aspirin. These 
results explain why increasing aspirin dosage or aspirin addition to other drugs may lessen anti-thrombotic 
protection. 
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Introduction 
 
Cardiovascular diseases are the leading cause of death and disability worldwide  (1). They are associated with 
the formation of arterial thrombi following excessive platelet activation and aggregation at disrupted vascular 
sites resulting in acute vessel occlusion and ischemic events  (2, 3). Aspirin has been the cornerstone of anti-
platelet therapy for more than 3 decades, with numerous trials demonstrating  that low doses of aspirin reduce 
the incidence of secondary cardiovascular events  (4–6). Recent studies have, however, raised doubts as to 
whether the previously observed benefits of aspirin in secondary prevention are maintained under current 
clinical care regimes where aspirin is often given together with a P2Y12 receptor antagonist, such as prasugrel or 
ticagrelor. For example, the Platelet Inhibition and Patient Outcomes (PLATO) trial reported an association 
between higher doses of aspirin and increased thrombotic risk in individuals taking ticagrelor  (7). Newer 
studies are therefore evaluating the benefits of low vs high dose aspirin in patients who have had previous 
cardiovascular events  (8) and whether aspirin discontinuation in favour of single drug therapy with a P2Y12 
receptor antagonist could retain anti-thrombotic efficacy  (9, 10). The first results of these trials indicate that 
low dose aspirin does not increase the protection from ischemic events afforded by ticagrelor  (11, 12).  
The platelet inhibitory effects of aspirin are explained by its ability to irreversibly inhibit cyclooxygenase 
(COX)-1 in platelets and therefore the conversion of AA to thromboxane (Tx)A2, an eicosanoid that promotes 
platelet aggregation and thrombosis  (13, 14). Importantly, platelet COX-1 also supports the production of other 
eicosanoids, including prostaglandins (PGs) such as PGE2, PGD2,  PGF2 (15)
, (16) and 11- and 15- 
hydroxyeicosatraenoic acid (HETE) (17–19), which have mixed actions on platelet activation, vascular function 
and thrombosis  (20–27).  
It has been hypothesized that the anti-platelet effect of aspirin mediated by inhibition of TxA2 is 
counterbalanced by aspirin inhibition of COX-1 and possibly COX-2 at non-platelet sites that reduces the 
synthesis of vasorelaxant and anti-aggregatory mediators such as PGI2  (28–30). However, the complete profile 
of eicosanoids whose synthesis is affected by the action of aspirin on platelet COX-1 and on other tissues and 
how it relates to the anti- and pro-thrombotic effects of aspirin has been so far poorly characterized.  
This has been difficult to appreciate because the pharmacokinetics and pharmacodynamics of aspirin are 
substantially different in mice and humans. Mice, in fact, require two hundred fold higher oral dose of aspirin 
than humans to achieve complete suppression of platelet COX-1 activity  (31, 32), but this dose of aspirin 
unavoidably affects COX activity in different body compartments.   
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While mice with global COX-1 knockout (COX-1-/-; hereafter, global-COX-1-ko mice) have been available for 
some time  (33), selective COX-1 cell-type deletion has only very recently been documented  (34, 35).  
Here we used mice with selective deletion of platelet COX-1 to mimic the selective effect of aspirin on platelet 
COX-1 eicosanoid synthesis. We compared this eicosanoid profile to those obtained in global-COX-1-ko mice, 
with lack of COX-1 activity in the entire body, and in mice treated with high dose aspirin to achieve COX 
enzyme inhibition in platelet and non-platelet targets. We described that aspirin affects different networks of 
AA-derived eicosanoids dependent upon its action on platelet COX-1 or on non-platelet COX targets. By 
interrogating Ingenuity Pathway Analysis (IPA), we found that loss of COX-1-related eicosanoids in platelets is 
anti-thrombotic, but loss of COX-1- and, possibly, COX-2-related eicosanoids in the remaining of the 
cardiovascular system limits aspirin’s anti-thrombotic effects. These findings were validated by assessing 
platetet aggregation in vitro and thrombus formation in vivo. These results could offer a mechanistic explanation 
as to why the addition of aspirin to other anti-thrombotic drugs or increase in aspirin dose does not add anti-
thrombotic benefit for human subjects and may increase thrombotic risk. 
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Materials and Methods 
 
Mice 
We used a Cre/loxP system to create transgenic mice with deletion of COX-1 in platelets. Floxed COX-1 mice 
(Ptgs1flox/flox mice) were generated by flanking exons 3 and 5 of the COX-1 gene with lox P sites in ES cells, 
which were injected into blastocysts to create chimeric mice with germline transmission. These animals have 
been deposited at Jackson Laboratories (USA) as strain no. 030884. COX-1fl/fl mice were then crossed with 
Pf4Cre mice (provided by Prof Steve Watson, University of Birmingham, United Kingdom, and used with the 
permission of Prof. Radek Skoda, University of Basel, Switzerland) to specifically delete COX-1 in the 
megakaryocyte lineage (Ptgs1flox/flox;Pf4Cre). Ptgs1flox/flox;Pf4Cre mice were mated with Ptgs1flox/flox mice to 
produce Ptgs1flox/flox;Pf4Cre mice (platelet-COX-1-ko mice) and Ptgs1flox/flox littermate controls (hereafter 
control mice). This strain was maintained on a mixed C57Bl/6 and 129S4/SvJae background. Global-COX-1-ko 
mice on a C57BL/6 background were generated as previously described (33). 
Animals were housed with free access to food (RM1; Special Diet Services, UK) and water under a 12h 
day/night cycle. Eight- to 12-week old mice were used for all experiments and all procedures described in this 
study were subject to UK Home Office approval (PPL 70/8422) under ‘The Animals (Scientific Procedures) 
Act (1986) Amendment Regulations (2012) following review by the Queen Mary University and Imperial 
College Animal Welfare and Ethical Review Board. Animals were randomized through allocation of sequential 
number at weaning (prior to genotyping) and experiments performed in this order. 
 
Complete blood counts and platelet preparation 
Mice were anesthetized with intraperitoneal (i.p.) ketamine (Narketan, 100 mg/kg; Vetoquinol, UK) and 
xylazine (Rompun, 10 mg/kg; Bayer, Germany) and blood was collected from the inferior vena cava. Complete 
blood counts were performed on blood collected in EDTA (IDEXX BioResearch, Germany). To prepare 
platelet-rich plasma (PRP) blood was anticoagulated with sodium citrate (0.32%; Sigma, UK), diluted 1:1 in 
modified Tyrode’s HEPES (MTH) buffer (containing 134 mmol/L NaCl, 2.9 mmol/L KCl, 0.34 mmol/L 
Na2HPO4, 12 mmol/L NaHCO3 and 1 mmol/L MgCl2 and 20mmol/L HEPES, pH 7.4; all Sigma, UK) and 
centrifuged at 100 g for 8 minutes, followed by centrifugation of the supernatant and the buffy coat at 100 g for 
6 minutes. The PRP was then used for immunofluorescence studies or to isolate platelets for immunoblot 
analysis. For the latter purpose, PRP was further centrifuged (750 g, 10 minutes) in the presence of PGI2 (PGI2, 
1 μg/mL; Tocris Bioscience, UK) and apyrase (0.02 U/mL; Sigma, UK). The resulting platelet pellet was 
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washed in MTH buffer containing 0.02 U/mL apyrase (Sigma, UK) and re-suspended to a final concentration of 
1 × 109 platelets/mL in MTH buffer. 
 
Immunoblot analysis 
1 × 109 platelets/mL (final) were resuspended in MTH buffer pH 7.4 containing protease inhibitor cocktail (5 
mmol/L EDTA; Complete; Roche Diagnostics, Sigma, UK) and lysed by the addition of Triton X-100 (0.5% 
v/v). Alternatively, snap-frozen tissues were homogenized in phosphate buffered saline (PBS) containing EDTA 
(10 mmol/L), Triton-X 100 (1%), phenylmethylsulfonyl fluoride (1 mmol/L), and protease inhibitor mixture 
(1×) using a Precellys 24 homogenizer (Bertin Instruments, France). SDS-PAGE and immunoblotting of cell 
lysates were performed using standard protocols. Membranes were probed with primary antibodies against 
mouse COX-1 (rabbit anti-mouse polyclonal IgG; Cell Signaling Technology, New England BioLabs, UK; 
catalogue no. 4841S; 1:1000) and GAPDH (rabbit anti-mouse monoclonal IgG; Cell Signaling Technology, 
New England BioLabs, UK; catalogue no. 5174S; 1:10000) followed by secondary horseradish peroxidase–
conjugated goat anti-rabbit IgG antibody (Sigma, UK; catalogue no. 12-348; 1:10000). Proteins were detected 
by enhanced chemi-luminescence reaction (BioRad GE Healthcare, UK) using clear-blue X-ray film or an 
ImageQuant-RT ECL imaging system (GE Healthcare, UK). 
 
Immunostaining and Airyscan laser scanning confocal microscopy  
For platelet imaging the PRP was mixed with equal volumes of 8% paraformaldehyde in PBS and platelets were 
left to fix for 15 minutes at room temperature (36). Platelets were pelleted by centrifugation at 1000 g for 10 
minutes, washed with PBS, and resuspended in PBS plus 1% BSA. To image the mixed population of platelets 
and leukocytes, the buffy coat was isolated from the PRP and treated with Lyse/Fix solution (BD Bioscience, 
Germany) to break the erythrocytes and fix the rest of the cells that were washed and resuspended in saline 
solution. Platelets or the mixed population of platelets and leukocytes were spotted on coverslips and incubated 
for 90 minutes at 37°C with saturating humidity. The coverslips were rinsed with PBS and blocked for 60 
minutes with hybridization buffer (0.2% Triton X-100 in PBS plus 1% BSA and 2% donkey serum; Sigma, 
UK); then stained with primary antibodies against mouse -tubulin (mouse monoclonal antibody, clone B-5-1-
2; Sigma, UK, catalogue no. T5168; 1:200) and COX-1 (rabbit anti-mouse polyclonal IgG; Cell Signaling 
Technology, New England BioLabs, UK; catalogue no. 4841S; 1:100) diluted in the same buffer. After 
washing, cells were incubated for 60 minutes with Alexa 488-conjugated secondary antibody (donkey anti-
mouse polyclonal IgG H+L; Life Technologies UK; catalogue no. A-21202; 1:500) and Alexa 647-conjugated 
secondary antibody (donkey anti-rabbit polyclonal IgG H+L; Life Technologies UK; catalogue no. A-31573; 
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1:500), to detect -tubulin and COX-1, respectively, and with DAPI (25 μg/mL; Life Technologies, UK) (10 
minutes), washed, post-fixed, and mounted on slides with fluorescent mounting medium (Life Technologies, 
UK). Images were acquired with an oil immersion objective (plan-Apochromat 63X/1.4 Oil DIC M27) using an 
LSM 880 confocal fluorescence microscope, AxioObserver, equipped with 4 lasers (Diode 405-30/ Argon 
458,488,514/DPSSS 561-10/HeNe 633), a Z-piezo stage insert and an AiryScan Detector. Immunostaining 
conditions, laser intensity and exposure settings were established with minimal/undetectable levels of 
autofluorescence, channel crosstalk and non-specific primary/secondary background fluorescence. Acquisition 
and maximum intensity projection rendering of the images was performed with Zen software (version 2.3 SP1, 
Zeiss, Germany). Images were exported to ImageJ (version 1.51a, NIH, USA) for final preparation. All images 
shown in the text are representative of at least 3 independent preparations. 
 
Aorta immunostaining 
COX-1 expression in the aorta was assessed as previously described (37). Mice killed with CO2 were 
immediately perfused across the heart with PBS (20 mL) followed by 5% formalin (20 mL), and the aorta was 
carefully removed. The aortic tissue was then blocked (20% normal goat serum; Vector Laboratories, UK) and 
permeabilized (0.1% Triton X-100), before being treated with primary antibody against mouse COX-1 (rabbit 
anti-mouse polyclonal IgG; Cayman Chemical, USA; catalogue no. 160109; 1:50) followed by Alexa 568-
conjugated goat anti-rabbit IgG secondary antibody (Life Technologies, UK; catalogue no. A-11036; 1:200). 
Tissues were counterstained with Alexa 488-conjugated anti-CD31 (rat anti-mouse monoclonal IgG2a,k; clone 
MEC13.3; Biolegend, USA; catalogue no. 102514; 1:100). After staining, aortic rings were cut open to reveal 
the luminal surface, mounted flat between a glass slide and coverslip with aqueous hard-set media (Vector 
Laboratories, UK), and pressed until the media had firmly set. The luminal surface of aortic rings was 
visualized with a Leica SP5 inverted confocal microscope using a 63× objective oil immersion lens. Laser and 
gain settings were fixed at the beginning of each imaging protocol.  Nonspecific binding was excluded by 
subtracting the fluorescence of tissue in which the primary antibody was omitted from the staining protocol. 
Images were exported to Image J (version 1.51a, NIH, USA) for final preparation. 
 
Enzymatic immunoassay for 6-keto-PGF1α measurement  
Aortic tissue, collected as previously described (37) < 10 minutes after mouse death, was perfused with PBS 
and dissected into small rings (∼2-mm) before being placed into individual wells of 96-well microtiter plates 
(Greiner Bio-one, UK) containing DMEM (200 mmol/L L-glutamine; Sigma, UK). After 30 minutes of 
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vigorous shaking at 37°C, the media were collected and 6-keto-PGF1α measured by ELISA (Enzo Life Sciences, 
USA).     
 
Measurement of circulating or stimulated total lipid mediators                                        
To stimulate the release of lipid mediators in vitro, blood was treated with 50 mol/L A23187 (Sigma, UK) or 
its vehicle under stirring conditions in a light transmission aggregometer for 5 minutes. 100 mol/L diclofenac 
sodium (Sigma, UK) and 100 U/mL heparin (Leo Laboratories, UK) were added at the end of the activation 
process and plasma prepared by centrifuging the blood (12000 g, 3 minutes, 4°C). Plasma samples were stored 
at -80°C until lipidomic analysis. 
For the analysis of the lipid mediators released in vivo, mice were anesthetized with ketamine and xylazine (i.p.) 
prior to intravenous (i.v.) injection with vehicle (saline) or aspirin (10mg/kg; Flectadol, Sanofi, Italy).  After 10 
minutes, the synthesis of lipid mediators was stimulated by i.v. injection of arachidonic acid (AA; 2.8 mg/kg; 
Sigma, UK) and blood withdrawn from the inferior vena cava into lepirudin 5 minutes later. Some mice were 
injected with vehicle (10% EtOH, 90% saline) rather than AA for measurement of the basal circulating levels of 
products. Plasma samples were prepared by centrifuging the blood (12000 g, 3 minutes, 4°C) and stored at -
80°C until lipidomic analysis. 
 
Liquid chromatography tandem mass spectrometry analysis of lipid mediators 
Lipidomic analysis was performed by liquid chromatography tandem mass spectrometry (LC-MS/MS), as 
previously described  (38, 39). Briefly, 250 µL mouse plasma was spiked with 30 ng each internal standard, 
mixed with 1 vol of 0.1% acetic acid in 5% methanol containing 0.01 mmol/L butylated hydroxytoluene, and 
extracted with 3 mL ethyl acetate. Ethyl acetate was passed through Maestro A columns (Tecan, Mannedorf, 
Switzerland) under gravity flow into glass tubes containing 6 µL of 30% glycerol in methanol. Columns were 
washed with 1 mL acetonitrile and samples were dried by vacuum centrifugation at 37°C, and reconstituted in 
30% ethanol. AA-derived metabolites were then separated by reverse-phase HPLC on a 1 x 150 mm, 5 m 
Luna C18 (2) column (Phenomenex, USA) and quantified using an MDS Sciex API 3000 triple quadrupole 
mass spectrometer (Applied Biosystems, USA) with negative-mode electrospray ionization and multiple 
reaction monitoring. 
 
Platelet aggregation in whole blood 
Platelet aggregation was assessed in whole blood as previously described (40). Briefly, half-area 96-well 
microtiter plates (Greiner Bio-One, UK) were precoated with hydrogenated gelatin (0.75% wt/vol; Sigma, UK) 
 
 
 
 
10 
in PBS to block nonspecific activation of blood. AA (0.05-0.5 mmol/L; Sigma, UK) or its vehicle were then 
added to each well, followed by whole blood. The plate was then placed onto a heated plate shaker (Bioshake 
IQ, Q Instruments, Germany) at 37°C for 5 minutes mixing at 1200 rpm to facilitate platelet aggregation. 
Following mixing, 5 L of whole blood was removed from each well and diluted 1:10 into an acid citrate 
dextrose solution (5 mmol/L glucose, 6.8 mmol/L trisodium citrate, 3.8 mmol/L citric acid). In some 
experiments, blood was pre-incubated with aspirin (30 μmol/L; Sigma, UK) or its vehicle for 30 minutes at 
37°C. Platelets were labelled with fluorescein isothiocyanate (FITC) or allophycocyanin (APC) conjugated anti-
CD41 (monoclonal rat anti-mouse, clone MWReg30;  Biolegend, UK; catalogue no. 133913; 1:100) or anti- 
CD42d-phycoerythrin (PE) (monoclonal hamster anti-mouse/rat, clone 1C2; Biolegend, UK; catalogue no. 
148503; 1:100) for 30 minutes. Samples were then diluted 1:50 in PBS containing 0.1% formalin (Sigma, UK), 
0.1% dextrose, and 0.2% BSA before addition of 10
4 CountBright absolute counting beads (Thermo Fisher 
Scientific, UK). Labelled, diluted blood was then analysed using a FACSCalibur flow cytometer (BD 
Biosciences, Germany) to determine platelet count. 
 
FeCl3-induced carotid artery thrombosis model                                                                                
Mice were anesthetized by i.p. injection of ketamine/xylazine (100/10 mg/kg body weight). Aspirin (10mg/kg; 
Flectadol; Sanofi, Italy) or saline were administered i.v. and, after 10 minutes, the left common carotid artery 
was exposed. A miniature Doppler flow probe (Transonic) was placed around the artery and a 5% FeCl3 
(Sigma, UK)-soaked piece of filter paper (1 × 2 mm) was applied for 3 minutes to induce thrombus formation. 
Blood flow was monitored for 30 minutes and the vessel occlusion time was set as cessation of blood flow for 
>30 seconds. 
 
Principal Component Analysis and Hierarchical Clustering Analysis 
Lipid mediator abundance, expressed as ng/mL, was filtered to remove those with no signal in any sample. Data 
were normalised against the non-stimulated samples and the dataset was uploaded to the Partek Genomics Suite 
(Partek, USA) for Principal Component Analysis (PCA).  PCA is a multivariate analysis that provides a visual 
representation of the dataset with score plots that show the systematic clusters among the observations (closer 
points represent higher similarity in the measurements). Data were also uploaded in the Partek (v6.6) software 
to perform hierarchical clustering using a Euclidean dissimilarity matrix.  
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Ingenuity Pathway Analysis 
The data set containing eicosanoids identifiers and corresponding fold changes and P-values was uploaded onto 
Ingenuity Pathways Analysis (IPA) (01-13) software (QIAGEN, USA) and each eicosanoid identifier was 
mapped in the Ingenuity Pathways Knowledge Base (IPKB) to find cellular functions and diseases that were 
significantly associated with differentially synthesized eicosanoids. Fisher’s exact test was performed to 
calculate a P-value determining the probability that each biological function and/or disease assigned to the data 
set was due to chance alone. Downstream effect analysis was used to predict changes in diseases and functions 
based on the direction of the change of the measured eicosanoids. In addition, networks were generated as 
graphical representations of the molecular relationships between eicosanoids and cellular functions.   
 
Statistical analysis 
For statistical analysis, GraphPad Prism 8.0 (USA) was used to perform t-test, one- and two-way ANOVA 
followed by Tukey’s test. P values < 0.05 were considered statistically significant  
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Results 
Characterization of platelet-COX-1-ko mice  
Platelet-COX-1-ko mice were viable, fertile and demonstrated a normal Mendelian inheritance ratio. They had 
normal platelet, erythrocyte, lymphocyte and neutrophil counts compared to their littermate controls, but 
slightly decreased monocyte counts (Supplemental Table 1). Western blot analysis and immunofluorescence 
staining confirmed the absence of COX-1 in platelets (Fig. 1A and 1B).  COX-1 was still present in leukocytes, 
aortic endothelial cells (Fig. 1C and 1D) and homogenates of kidney and lungs (Fig. 1E). In comparison, COX-
1 was not expressed in the blood cells or in other tissues collected from global-COX-1-ko mice (Fig. 1C, 1D 
and 1F). The effects of platelet COX-1 deletion on endothelial function were evaluated by measuring the levels 
of PGI2, the main COX-1-derived eicosanoid produced by the endothelium (37). We first measured the 
production by aortic rings of PGI2, determined as its breakdown product, 6-keto-PGF1, and found similar 
levels in incubates of tissues from control (12.912.92 ng/mL; n=3) and platelet-COX-1-ko (8.920.62 ng/mL; 
n=3) (P=0.66) mice whereas levels in incubates from global-COX-1-ko mice were reduced by more than 95% 
(0.550.01 ng/mL; n=3) (P=0.03 vs control mice). Basal circulating levels of 6-keto-PGF1 in the blood tended 
to be higher in platelet-COX-1-ko mice (33999 pg/mL, n=4) and control mice (21411 pg/mL, n=4) than in 
global-COX-1-ko mice (607 pg/mL, n=4).  
 
Eicosanoid profile of in vitro-stimulated whole blood and prediction of thrombosis-related functions 
In vitro stimulation of whole blood with the Ca2+ ionophore, A23187, was used to induce receptor-independent 
activation of platelets and leukocytes. Thirty different released lipid mediators were detected by LC-MS/MS in 
blood collected from control mice, platelet-COX-1-ko mice and global-COX-1-ko mice. These data were 
subjected to Principal Component Analysis (PCA) and hierarchical clustering analysis. According to the PCA 
analysis, lipid profiles were distinct for each mouse type; however, platelet-COX-1-ko and global-COX-1-ko 
mice were closely associated (data not shown). In particular, hierarchical clustering analysis of the lipid 
measurements identified three different clusters of AA-derived eicosanoids (Fig. 2A; red, blue and green 
outlined boxes) which are shown in further detail in Figure 2B (red, blue and green outlined boxes). In the 
control mice, TxB2, the stable metabolite of TxA2, PGF2, 11-HETE and 15-HETE (cluster in red) were all 
markedly increased by incubation of whole blood with A23187. However, these increases were not observed in 
blood from platelet-COX-1-ko or global-COX-1-ko mice. Together, our data shows that the increases in these 
eicosanoids in whole blood result from the activity of platelet COX-1. The productions of PGE2 and PGD2 
(cluster in blue) in response to A23187 were significantly reduced in both platelet-COX-1-ko and global-COX-
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1-ko mice, although not abolished, meaning that in whole blood the formation of PGE2 and PGD2 may also 
derive from COX-2 activity in other blood cells. Syntheses of 12-HETE, 5-HETE and LTB4 (cluster in green), 
the first a product of 12-lipoxygenase (LOX) activity in platelets and the last two of 5-LOX activity in 
leukocytes, were not affected by either systemic or platelet-specific COX-1 deletion. 
Ingenuity Pathway Analysis (IPA) was used to predict platelet functions and thrombosis-related processes 
changed on the basis of the measurements of AA COX products synthesised in vitro. Platelet activation was 
predicted as decreased for both platelet-COX-1-ko and global-COX-1-ko mice compared to control mice, and 
platelet aggregation, morphology and adhesion and carotid artery thrombosis resulted as affected (Fig. 2C). 
Mainly reduced TxA2 and PGE2 contributed to the eicosanoid network supporting these functional predictions 
(Supplemental Fig. 1). These data imply that, in vitro, aspirin inhibition of COX-1 activity in platelets and in 
other blood cells has similar anti-thrombotic effects, due to the inhibition of similar eicosanoid networks.    
 
Characterization of the profiles of lipid mediators released upon administration of AA in vivo and 
predicted influences on thrombosis 
Intravenous injection of AA (2.8 mg/kg) to control mice resulted in the generation of 36 distinct metabolites 
derived from AA, linoleic acid (LA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (Fig. 3A 
provides the data for AA COX products; Supplemental Table 2 supplies the data for AA non-COX products, as 
well as LA, DHA and EPA products; Supplemental Table 3 supplies the retention time and tandem MS 
calibrations for AA COX products). As well as inducing the production of a variety of lipid mediators, the 
injection of this dose of AA also reportedly induces platelet aggregation and thrombosis (41). Distinct profiles 
of AA COX eicosanoids were subsequently established for: (i) control mice; (ii) control mice treated with 
aspirin (10mg/kg, i.v.); (iii) platelet-COX-1-ko mice; (iv) platelet-COX-1-ko mice treated with aspirin; and (v) 
global-COX-1-ko mice. These profiles were grouped in different clusters according to both PCA (data not 
shown) and hierarchical clustering analysis (Fig. 3B); platelet-COX-1-ko mice (orange) clustered distinctly 
from control mice (yellow), but also from global-COX-1-ko mice (blue), aspirin-treated control mice (green) 
and aspirin-treated platelet-COX-1-ko mice (red), the last three being closely associated. 
IPA of the levels of AA COX products released in vivo predicted overall protection from thrombosis for 
platelet-COX-1-ko mice, but not for aspirin-treated control or global-COX-1-ko mice. In particular, while the 
main cellular functions regulating platelet reactivity and thrombosis of the carotid artery were predicted to be 
reduced in platelet-COX-1-ko mice, they were predicted to be increased in both aspirin-treated control mice and 
global-COX-1-ko mice (Fig. 3C). The eicosanoid networks associated with predicted reduction in platelet 
reactivity and thrombosis were dominated by dramatically reduced TxA2 and marginal reduction of PGE2 in 
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platelet-COX-1-ko mice versus control mice. Conversely, decreased production of PGI2, in aspirin-treated 
control mice, and of PGI2 and PGD2, in global-COX-1-ko mice, underpinned the predicted increase of platelet 
reactivity and thrombosis (Supplemental Fig. 2).  
These data implied that aspirin’s inhibition of eicosanoids other than platelet derived TxA2 could lead to a 
detrimental pro-thrombotic effect of aspirin. To further support these findings, we performed additional 
analyses to predict changes in vascular function that could also affect thrombosis. IPA predicted arterial 
relaxation and contraction to be increased and decreased, respectively, in platelet-COX-1-ko mice; conversely 
vasodilation and blood flow were predicted to be decreased in aspirin-treated control mice or global-COX-1-ko 
mice, with a predicted increase of blood pressure and hypertension which predisposes to thrombosis 
(Supplemental Fig. 3).  
Networks of eicosanoids linked to predicted increase of vasorelaxation in platelet-COX-1-ko versus control 
mice similarly featured shifts in TxA2 and PGE2 and additionally marginal changes in the PGF2α pathway. 
Whilst reduced synthesis of PGI2 was linked to the predicted increase of vascular tone and blood pressure in 
aspirin-treated controls and global-COX-1-ko mice (Supplemental Fig. 4).  
 
Validation of the functional consequences of selective blockade of platelet COX-1 versus whole body 
actions of aspirin  
The IPA predictions of reduced platelet activation in both platelet- and global-COX-1-ko mice, based on COX-
derived eicosanoid networks established upon in vitro whole blood stimulation, were validated using AA-
induced platelet aggregation in whole blood. Platelet aggregation was reduced in platelets from both platelet-
COX-1-ko mice (95% aggregation, P= 0.04) and global-COX-1-ko mice (8.028.02, P=0.06), compared to 
control mice (6224% aggregation).  
Thrombosis within the carotid artery was used as a model to verify the IPA predictions made on the basis of in 
vivo established COX-dependent eicosanoid networks. As predicted platelet-COX-1-ko mice demonstrated a 
significantly prolonged time for vessel occlusion compared to controls (Fig. 4), that was normalized by 
additional treatment with aspirin (Fig. 4A). 
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Discussion 
Numerous studies have demonstrated that prophylactic treatment with low-dose aspirin reduces the recurrence 
of arterial thrombotic events (4). However, recent reports have questioned the optimal dose of aspirin to use and 
the true cardiovascular benefits of aspirin in combination with other, newer therapies (5–8, 11, 12). While 
clinical studies have been put in place to answer these questions (7–12), an improved understanding of the 
efficacy of anti-thrombotic therapies that involve aspirin requires better evaluation of the mechanisms of action 
of aspirin on platelets and on other targets within the cardiovascular system. However, basic research studies 
addressing the actions of low dose aspirin in humans provide limited information (31, 42–44) and studies using 
mice are hard to translate to humans because relatively very high oral aspirin doses are required to inhibit 
mouse platelet COX-1 (32, 45, 46); these elevated aspirin levels affect multiple other sites in the body. In the 
present work we used platelet COX-1 ko mice to model the specific effects of aspirin on platelet COX-1 and to 
define the profile of platelet-derived eicosanoids affected by aspirin. By using global-COX-1-ko mice and 
treating mice with aspirin we characterized the profile of eicosanoids affected by lack of COX-1 and of COX-1 
and COX-2 activity, respectively, in the remainder of the body. Finally, we linked the anti- and pro-thrombotic 
effects of aspirin to the eicosanoid networks affected and particular platelet and non-platelet derived eicosanoids 
(Fig. 5) . 
After confirming the selective deletion of COX-1 in platelets and the maintenance of COX-1 at other important 
cardiovascular sites, notably the endothelium, we characterised the production of lipid mediators in whole blood 
in vitro and quantified thirty compounds. Deletion of platelet COX-1 was notably associated with marked 
reductions in the production of the eicosanoids TXA2, PGF2, 11-HETE and 15-HETE. These results support 
the idea that inhibition of TxA2 synthesis by platelets is the primary mechanism underlying the effect of aspirin 
in the cardiovascular system, but also suggest that additional eicosanoids dependent upon platelet COX-1 
activity play roles in the net anti-thrombotic action of aspirin. This conclusion is consistent with our report that 
aspirin reduces the production of 11- and 15-HETE in whole blood (19). We also identified for the first time 
PGF2 as a platelet-derived prostaglandin dependent on COX-1 activity. It has been recently suggested that 
PGF2 acts on EP and TP receptors on platelets and enhances platelet activation (47), which may explain some 
of the effects we observed. Moreover, strong evidence suggests that 15-HETE potentiates platelet aggregation, 
decreases PGI2 synthesis in endothelial cells, induces vasoconstriction and reduces the inhibitory activity of 
nitric oxide, while stimulating endothelial and smooth muscle cell proliferation and migration (19, 48–50). 
Therefore modulation of COX-1 platelet derived 15-HETE and PGF2 may influence pathologies such as 
diabetes, myocardial infarction, atherosclerosis, hypertension or cancer and their inhibition by aspirin may 
underpin some of the drug’s beneficial effects (51, 52).  
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Our data also demonstrate that the production of PGE2 and PGD2 by whole blood are partly dependent upon 
platelet COX-1, with the residual synthesis of these prostaglandins in platelet-COX-1-ko mice being consistent 
with production by COX enzymes at other cellular sites. In vitro, PGE2 both inhibits and potentiates platelet 
aggregation, depending on its concentration and local receptor expression (14). Although PGD2 has been long 
regarded as a main macrophage product, Song et al. have recently demonstrated that platelet activation evokes 
the synthesis of PGD2 and this response is repressed in healthy volunteers receiving low dose aspirin (21). 
PGD2 interacts with platelet DP1 receptors and constrains platelet activation by increasing the activity of 
adenylyl cyclase (20, 21). It also restrains thrombosis and atherogenesis in vivo  (21), suggesting that PGD2 
inhibition can produce a pro-thrombotic effect.  
A possible limitation of our findings is that the formation of PGF2, PGE2 and PGD2 in platelets might result 
from the non-enzymatic degradation of PGH2. If so in our studies, particular examination of the respective PG 
synthetases would be required to confirm the production of these metabolites by platelets. However, various 
other studies have pointed to a synthetase-dependent metabolism of PGH2 in platelets. For instance, blockage of 
TxA2 synthetase in human platelets is associated with an increased synthesis of prostaglandins, including 
PGF2, PGE2 and PGD2  (53, 54), and immunodepletion of lipocalin-like PGD synthase suppresses PGD2 
formation in platelets stimulated with ADP (21).  
Overall the combined loss of platelet-derived COX-1 products, TxA2 and PGE2, in the platelet COX-1 mouse 
was associated with a reduction in platelet activation, as suggested by IPA and as we verified in platelet 
aggregation experiments, consistent with the widely reported anti-platelet effects of aspirin. Importantly, the 
productions in whole blood of the non-COX-1 dependent products, 5-HETE, 12-HETE and LTB4 were 
unaffected by deletion of platelet COX-1 supporting the selectivity of the model.   
The effects of platelet COX-1 deletion seen in blood in vitro were partially recapitulated in vivo.  Notably the 
production of TXA2 was still greatly reduced.  However, reductions were not seen in the levels of PGE2, PGF2, 
11-HETE and 15-HETE indicating that in vivo platelets are at best minor contributors to the overall production 
of these eicosanoids. Alternatively, HETE and EET products could have been present in the AA injected to 
stimulate the release of eicosanoids in vivo, as a result of the autoxidation of the fatty acid (data not shown) 
which could explain why we did not find differences for the in vivo synthesis of 11-HETE and 15-HETE across 
the different mouse lines and treatments. Most notably, unlike global-COX-ko mice or control mice treated with 
aspirin, platelet-COX-1-ko mice had circulating levels of 6keto-PGF1 that were not different from those of 
control mice. This result is consistent with maintenance of endothelial PGI2 production as demonstrated by 
presence of COX-1 in endothelial cells and production of PGI2 by isolated aortas, and confirms our finding that 
endothelial COX-1 is a relevant source of this potent endogenous inhibitor of platelets and thrombosis (34, 37).  
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The alterations in eicosanoid profile in platelet-COX-1-ko mice in vivo were associated by IPA with reduction 
in cardiovascular disease. In particular, the changes in the network of eicosanoids driven by reductions in 
platelet COX-1 dependent TxA2 and PGE2 were associated with reduced platelet activation and aggregation, and 
so reduced thrombosis of the carotid artery. The networks seen in aspirin-treated control mice and global-COX-
1-ko mice were not associated with an anti-thrombotic influence, but rather with a pro-thrombotic phenotype, 
consistent with reduced synthesis of anti-thrombotic mediators PGI2 and PGD2. The networks for the aspirin-
treated control mice and global-COX-1-ko mice also indicated greater drives towards vasoconstriction than 
predicted for platelet-COX-1 mice, consistent with suggestions that TxA2 and PGI2 have antagonistic actions on 
vascular tone; TXA2 being a potent vasoconstrictor and PGI2 a potent vasodilator.  Notably, vasoconstriction 
promotes thrombosis (55). These findings were further confirmed by IPA predictions of reduced synthesis and 
accumulation of vasorelaxant mediators and signalling molecules, including cyclic adenosine monophosphate, 
nitric oxide and cyclic guanosine monophosphate in aspirin-treated control mice (data not shown). In particular, 
reduced synthesis and signals of nitric oxide could be related to increased levels of asymmetric 
dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase, that could have been 
caused by COX-2 inhibition by aspirin. In fact, some of our group have recently reported that lack of COX-2 in 
mice or treatment with a COX-2 selective inhibitor leads to increased levels of ADMA in the plasma (56, 57). 
Finally, to validate IPA predictions derived by the measurement of AA COX products in vivo, we compared the 
effects of loss of COX-1 activity in platelets and the effects of aspirin on non-platelet targets in a model of in 
vivo thrombosis. As predicted, platelet-COX-1-ko mice had an anti-thrombotic phenotype compared to control 
mice. Similarly, as predicted, addition of aspirin to platelet-COX-1-ko mice reduced the time to reach vascular 
occlusion indicating an increase in thrombosis. For this study, we used acute i.v. injection of a single dose of 
aspirin (10 mg/kg) which can reduce both COX-1 and COX-2 activity. However, we conclude that the 
prothrombotic effect of aspirin we observed is explained by inhibition of COX-1 rather than COX-2. This 
conclusion is supported by our recent report that acute COX-2 inhibition does not affect thrombosis but that 
selective deletion of COX-1 from endothelial cells is pro-thrombotic, with this latter effect overcome when 
COX-1 is deleted from both endothelial cells and platelets (34). We have previously shown that i.v. doses of 
aspirin lower than the one used for the present study have non-platelet effects (58), therefore we did not explore 
the effect of escalating doses of aspirin on lipid mediator formation and thrombosis.  
In conclusion, our results demonstrate that the cardiovascular actions of aspirin mediated through inhibition of 
platelet COX-1 or of extra-platelet aspirin targets can be explained by profiling in vitro and in vivo eicosanoid 
formation. These in vitro and in vivo profiles definitively show that while in vitro aspirin mimics the effect of 
specific platelet COX-1 inhibition, in vivo aspirin has additional non-platelet effects on eicosanoid formation 
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that promote thrombosis. Our study suggests a mechanistic explanation for the main findings of recent trials 
showing no additive antithrombotic effect of aspirin when in combination with P2Y12 receptor antagonists (11, 
12). In agreement with previous reports (59, 60), this study also shows the potential of combining 
comprehensive lipidomic analysis with platelet function analysis to assess the effectiveness of anti-thrombotic 
treatments and establish the potential for individualized anti-thrombotic drug regimes. The responses of an 
individual to aspirin are a net response resulting from the state of the platelet and the networks of eicosanoids 
being produced at platelet and non-platelet sites.  
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 Figure Legends 
 
Figure 1. Characterization of platelet COX-1 deletion. (A) Control and platelet-COX-1-ko platelet lysates were 
subjected to SDS-PAGE and probed for COX-1 and GAPDH as indicated. (B) Fixed and permeabilized platelets 
from control and platelet-COX-1-ko mice were stained for tubulin (green) and COX-1 (magenta) and imaged with 
Airyscan laser scanning confocal microscopy. Bars represent 2 m. (C) The buffy coat was prepared from global-
COX-1-ko, control and platelet-COX-1-ko mouse blood with the mixed platelet and §leukocyte populations being 
isolated prior to staining for tubulin (green), DAPI (blue) and COX-1 (magenta) and imaging. Bars represent 10 
m. (D) Aortas from global-COX-1-ko, control and platelet-COX-1-ko mice were fixed, permeabilized and 
stained for COX-1 (magenta) and the endothelial marker CD31 (green). Aortas were then dissected into rings that 
were cut open to visualise their luminal surface by confocal microscopy. Bars represent 50 m. (E and F) Kidney 
cortex (Kc), kidney medulla (Km), lungs (L) and platelet lysates were subjected to SDS-PAGE and probed for 
COX-1 presence. The images are representative of at least 4 mice per group.  
 
Figure 2. Tandem mass spectrometry analysis of lipid mediators produced in whole blood and Ingenuity 
Pathway Analysis (IPA) predictions of platelet activation and thrombosis. Plasma samples were prepared 
from mouse blood following incubation in vitro with vehicle or A23187 (50 M) in stirring conditions (1000 rpm, 
5 minutes) and subjected to tandem mass spectrometry analysis. (A) Relative levels of mediators displayed in a 
heat map using a Z-score ranging from -4.12 (blue) to 4.12 (red). The individual products are represented on the 
bottom horizontal bar and their clustering on the top, while on the left the metabolites are grouped according to 
stimulated and unstimulated conditions and to the mouse strain. Hierarchical clustering analysis identified 3 
different clusters of eicosanoids whose levels are significantly increased upon stimulation of whole blood with 
A23187 (50 M): the cluster including TxB2, PGF2, 11-and 15-HETE is indicated in the red box; the cluster 
including PGE2 and PGD2 is indicated in the blue box; and the cluster comprising 12-HETE, 5-HETE and LTB4 
in the green box. (B) The absolute plasma levels of these eicosanoids as measured by tandem mass spectrometry. 
Results are from n=4 global-COX-1-ko, control and platelet-COX-1-ko mice for each vehicle or A23187 
treatment and were analysed by two-way ANOVA followed by Tukey’s test. Data are presented as means  SEM. 
*P<0.05. **P<0.01. ***P<0.001. ****P<0.0001. (C) IPA and downstream effects analysis were used to predict 
the cellular events related to platelet reactivity and thrombosis affected by the increase or decrease of AA-derived 
eicosanoids synthesis by COX in vitro in platelet-COX-1-ko mice and global-COX-1-ko mice. In the bar charts, 
the disease and function categories involved in this analysis are displayed along the y-axis. The x-axis displays 
the -(log) significance. Longer bars are more significant than shorter bars. Functions are listed from most 
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significant to least and the vertical dotted line denotes the cu-toff for significance (p-value of 0.05). Blue and grey 
indicates diseases or functions that are predicted as decreased or affected, respectively 
 
Figure 3. Tandem mass spectrometry analysis of eicosanoids produced in vivo and IPA predictions for 
platelet reactivity and thrombosis. (A) Mass spectrometry measurements of COX-derived eicosanoids induced 
by systemic injection of AA (2.8 mg/kg, i.v.). Data are meansSEM, n=4-6 mice per group. *P < 0.05, **P < 
0.01, ***P < 0.001 and ****P < 0.0001 (1-way ANOVA followed by Tukey’s post-hoc test). (B) The relative 
levels of eicosanoids are displayed in a heat map using a Z-score ranging from -4.20 (blue) to 4.20 (red). The 
individual products are identified on the bottom horizontal bar and their clustering on the top, while on the left 
the clustering of the mice depending on their eicosanoid signatures is shown. (C) IPA was used to predict changes 
in processes linked to platelet reactivity and thrombosis based on the determination of in vivo eicosanoid 
synthesis. The bar charts show the most significant changes in platelet-COX-1-ko mice, aspirin-treated control 
mice and global-COX-1-ko mice. Functions are listed from most significant to least. The x-axis displays the -(log) 
significance and the vertical dotted line denotes the cut-off for significance (p-value of 0.05). Blue, red and grey 
indicate diseases or functions that are predicted as decreased, increased or affected, respectively.  
 
Figure 4. In vivo thrombosis. (A) In vivo thrombus formation was studied in the carotid artery in response to 
exposure to 5% FeCl3 for 3 minutes. The time to occlusion was quantified in control mice and platelet-COX-1-ko 
mice under control conditions or following treatment with aspirin (10 mg/kg, i.v.). The data are meansSEM, 
n=6-8 mice per group. *P < 0.05 (one-way ANOVA followed by Tukey’s post-hoc test). (B) Traces of blood flow 
rate in carotid arteries during thrombosis model in (blue line) control mice and (red line) platelet-COX-1-ko mice. 
 
Figure 5. Model comparing the effects of aspirin in platelets vs the endothelium. (A) Aspirin’s action in 
platelets, that is mimicked in p-COX-1-ko mice, results in the inhibition of COX-1-dependent pro-thrombotic 
eicosanoids, including TxA2, PGE2 and PGF2, and in a beneficial anti-thrombotic effect. (B) In the vasculature, 
aspirin blocks the activity of COX-1 and COX-2 and the synthesis of anti-thrombotic and vasorelaxant mediators, 
including PGI2 and PGD2. This effect favours thrombosis thus countering and limiting the beneficial effects of 
aspirin on the cardiovascular system mediated through inhibition of COX-1 in platelets.  This figure was produced 
using Servier Medical Art (http://www.servier.com). 
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                                               Table S2. Metabolites measured in whole blood after in vivo stimulation with AA. The data are reported as means ± SEM, n=5-6.  
 
  control control+aspirin platelet-COX-1-ko platelet-COX-1-ko+aspirin global-COX-1-ko 
5-HETE 213.862±16.358 271.336±26.468 319.598±57.551 273.834±14.021 239.516±40.075 
8-HETE 220.572±15.672 282.066±27.714 327.814±59.009 279.257±14.280 251.950±42.295 
12-HETE 1356.153±95.468 1739.243±166.066 2043.025±369.575 1729.632±96.574 1544.734±266.885 
19-HETE 0.251±0.059 0.747±0.121 0.173±0.027 0.157±0.053 0.141±0.029 
8,9-EET 0.197±0.107 1.440±0.432 0.777±0.111 1.04±0.210 0.769±0.242 
14,15-EET 0.161±0.037 1.174±0.538 0.223±0.01 0.461±0.092 0.289±0.033 
5,6-DHET 0.399±0.037 0.572±0.049 0.642±0.098 0.531±0.042 0.407±0.059 
8,9-DHET 1.432±0.136 1.640±0.201 1.866±0.224 1.343±0.07 1.423±0.131 
11,12-DHET 1.999±0.182 3.953±0.246 3.518±0.503 2.929±0.207 2.453±0.447 
14,15-DHET 2.405±0.266 5.391±0.353 4.132±0.528 3.501±0.243 2.691±0.367 
Lipoxin A4 0.496±0.014 6.612±3.931 0.723±0.098 1.045±0.053 0.454±0.053 
9-HODE 3.081±0.638 6.477±1.483 11.793±2.312 5.329±0.78 9.745±3.201 
13-HODE 19.044±3.734 32.099±12.928 49.707±10.286 19.538±2.875 37.674±9.397 
9,10-DHOME 4.68±0.899 5.586±1.836 3.904±0.691 2.632±0.303 4.144±0.288 
12,13-DHOME 13.831±2.694 17.186±5.233 11.481±2.062 7.187±0.864 13.556±1.086 
9,10-EpOME 4.470±0.681 4.702±1.533 3.428±0.583 3.762±1.05 3.996±0.398 
12,13- EpOME 4.105±0.617 3.899±1.407 2.595±0.398 3.322±0.997 3.319±0.552 
7,8-DiHDPA 0.486±0.048 0.432±0.087 0.319±0.031 0.997±0.029 0.464±0.045 
13,14-DiHDPA 0.287±0.050 0.569±0.114 0.259±0.034 0.23±0.028 0.273±0.015 
16,17-DiHDPA 0.639±0.119 1.539±0.324 0.599±0.076 0.481±0.058 0.624±0.041 
19,20-DiHDPA 2.6±0.401 4.587±0.695 1.751±0.18 1.546±0.228 2.071±0.195 
7,8-EpDPA 58.739±6.318 60.835±3.991 78.215±8.029 69.039±6.388 117.179±9.395 
10,11-EpDPA 0.138±0.0176 0.079±0.008 0.152±0.01 0.107±0.015 0.287±0.032 
16,17-EpDPA 0.116±0.025 0.089±0.026 0.157±0.0157 0.129±0.029 0.336±0.052 
19,20-EpDPE 2.366±0.346 2.865±0.428 3.741±0.380 2.959±0.448 4.545±0.320 
17,18-DiHETE 4.889±1.149 6.099±1.166 4.622±0.718 3.545±0.636 3.497±0.290 
17,18-EpETE 0.643±0.085 0.411±0.079 0.605±0.055 0.433±0.0377 0.968±0.103 
AA  
NON-COX METABOLITES 
(ng/mL) 
LA METABOLITES 
(ng/mL) 
DHA METABOLITES 
(ng/mL) 
EPA METABOLITES 
(ng/mL) 
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Table S3. MS/MS calibration and retention time for the AA COX-1 metabolites measured 
upon whole blood stimulation in vivo with AA.  
compound Q1 Q3 Retention time 
    
6ketoPGF1a 369 163 1 
TXB2 369 169 1.8 
8isoPGF2a 353 193 1.8 
PGF2a 353 309 2.4 
PGE2 351 271 2.6 
PGD2 351 271.01 3 
Lipoxin B4 351 221 3.1 
15-HETE 319 219 9.8 
11-HETE 319 167 9.9 
 
 
 
 
35 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Bplatelet-COX-1-ko global-COX-1-ko
decreased eicosanoid production
inhibited disease/function 
activated disease/function 
functiondisease
affected disease/function 
Supplemental Figure 1. IPA-generated networks showing the association between AA-derived eicosanoids synthesised by COX 
in whole blood in vitro and predicted changes in platelet reactivity and thrombosis. Eicosanoids with decreased synthesis are 
displayed in green. Diseases and functions predicted as activated, inhibited or affected are displayed in orange, blue and grey,
respectively, for platelet-COX-1-ko mice (A) and global-COX-1-ko mice (B). 
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aspirin-treated controlsA B Cplatelet-COX-1-ko global-COX-1-ko
decreased eicosanoid production
inhibited disease/function 
activated disease/function 
functiondisease
affected disease/function 
Supplemental Figure 2. Networks illustrating the relationship between production of AA-derived eicosanoid by COX in vivo
and changes in platelet reactivity and thrombosis as predicted by IPA. The profile of eicosanoids whose synthesis is decreased 
(green) is shown for (A) platelet-COX-1-ko mice, (B) aspirin-treated control mice and (C) global-COX-1-ko mice. The association 
between these profiles and predicted activation (orange), inhibition (blue) or affected regulation (grey) of platelet function and 
thrombosis is shown. 
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Supplemental Figure 3. Ingenuity Pathway Analysis (IPA) of influences of AA-derived COX eicosanoid production 
patterns on vascular function. Bar charts illustrate up- and down-regulated diseases and functions related to vascular 
tone as predicted for (A) platelet-COX-1-ko mice, (B) aspirin-treated control mice and (C) global-COX-1-ko mice. 
Functions are ordered according to their -log significance, top ones are the most significant and bottom ones least 
significant. The dotted line represents the cut-off for significance set as p-value of 0.05. Blue, red and grey indicate 
diseases or functions that are predicted as decreased, increased or affected, respectively.
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aspirin-treated controlsA B Cplatelet-COX-1-kox global-COX-1-ko
decreased eicosanoid production
inhibited disease/function 
activated disease/function 
functiondisease
affected disease/function 
Supplemental Figure 4. Networks of AA-derived eicosanoids generated by COX activity in vivo and their association with IPA-
predicted changes of vascular function. Networks of eicosanoids found as decreased are illustrated in green for (A) platelet-COX-1-ko 
mice, (B) aspirin-treated control mice and (C) global-COX-1-ko mice (C). The association between these networks and predicted 
activation (orange), inhibition (blue) or affected regulation (grey) of vascular functions and related diseases is shown.
